Sustained antibody response to a linear epitope of Nipah virus fusion protein in human survivor serum samples
Tropical Biomedicine · 31.03.2026 · 43 (1) · 5-15
DOI: 10.47665/tb.43.1.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tropical Biomedicine, online erschienen am 31.03.2026. Verfasst von L J Ting und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Advanced Studies, Universiti Malaya, 50603 Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: Nipah Virus, Antibodies, Viral, Epitopes, B-Lymphocyte, Viral Fusion Proteins.
Abstract (Originalsprache)
Nipah virus (NiV), a pathogen with pandemic potential, lacks approved treatments or vaccines, highlighting the urgent need for research on immune-targeted antigenic determinants. A significant gap persists in NiV research, as studies on the fusion (F) protein critical for viral entry as well as the B cells epitopes, have primarily focused on computational prediction rather than experimental validation of immunogenic epitopes obtained through immunoinformatics approach. This study focused on the conserved F protein across NiV human isolates and employed an immunoinformatics approach to predict linear B-cell epitopes capable of direct immune activation. Predicted epitopes were screened for antigenicity, toxicity, and allergenicity. Molecular docking analysis was performed to evaluate its binding affinity with B-cell receptors (BCRs). To validate its immunogenicity, the LF6 peptide was synthesized and used in an indirect ELISA to test sera from cohort previously infected with NiV as well as with negative cohort. Epitope LF6 (LISNIEIGFCL) was identified as a strong candidate based on its immunogenic properties. Molecular docking showed favorable binding of LF6 with BCR. ELISA results revealed that one sera from the survival cohort showed positive response which is an IgG antibody response 2-fold higher (0.343) than the cut-off value (0.0171). This study provides the first reported evidence linking computational predictions with functional immune reactivity for a B-cell epitope of NiV. The findings suggest that LF6 has the potential to elicit specific immune responses. However, given the small sample size, further validation in larger cohorts is essential to confirm LF6's vaccine relevance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute for Advanced Studies, Universiti Malaya, 50603 Kuala Lumpur, Malaysia.
- Tropical Infectious Diseases Research & Education Centre (TIDREC), Universiti Malaya, 50603 Kuala Lumpur, Malaysia.
- Department of Chemistry, Faculty of Science, Universiti Malaya, 50603 Kuala Lumpur, Malaysia.
- Institute of Biological Sciences, Faculty of Science, Universiti Malaya, 50603 Kuala Lumpur, Malaysia.
- Department of Pharmaceutical Life Sciences, Faculty of Pharmacy, Universiti Malaya, 50603 Kuala Lumpur, Malaysia.
Zitieren
APA
Ting, L. J., Tan, X. L., Tiong, V., Abubakar, S., Abdullah, I., Karsani, S. A., Chan, K. G., Chua, K. O., Yong, H. S., & Liew, Y. J. M. (2026). Sustained antibody response to a linear epitope of Nipah virus fusion protein in human survivor serum samples. Tropical Biomedicine, 43(1), 5-15. https://doi.org/10.47665/tb.43.1.002
Vancouver
Ting LJ, Tan XL, Tiong V, Abubakar S, Abdullah I, Karsani SA, et al. Sustained antibody response to a linear epitope of Nipah virus fusion protein in human survivor serum samples. Tropical Biomedicine. 2026;43(1):5-15. doi:10.47665/tb.43.1.002
BibTeX
@article{Ting2026,
author = {Ting, L J and Tan, X L and Tiong, V and Abubakar, S and Abdullah, I and Karsani, S A and Chan, K-G and Chua, K-O and Yong, H-S and Liew, Y J M},
title = {Sustained antibody response to a linear epitope of Nipah virus fusion protein in human survivor serum samples},
journal = {Tropical Biomedicine},
year = {2026},
volume = {43},
number = {1},
pages = {5--15},
doi = {10.47665/tb.43.1.002}
}
EUVIMED